Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Finance

6 May 2022

MindMed Receives 700% Price Target From Roth Capital

Roth Capital Partners has initiated coverage on MindMed with a $7 price target, over 700% the current stock price....

By Jason Najum

Finance

5 May 2022

MindMed Files For $200 Million Raise

MindMed has quietly filed a prospectus with the SEC for a "mixed shelf" offering with proceeds of up to $200 million...

By Jason Najum

Industry

4 May 2022

New Study Shows Positive Results for Compass Pathways’ COMP360

COMPASS Pathways released recent results from two studies using the company's COMP360 compound....

By Jason Najum

Don’t Miss

2 May 2022

News You Might Have Missed: May 2nd, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

21 Apr 2022

Cybin Announces Partnership for CYB-003 Trial

Cybin has announced a partnership with a leading CRO (Clinilabs) to help them with their upcoming trial for lead candidate compound CYB-003...

By Jason Najum

Breaking News, Finance

19 Apr 2022

Nue Life Closes $23 million Series A Financing

Nue Life, a telemedicine startup building a mental wellness platform, has just closed a $23 million Series A equity financing....

By Jason Najum

Don’t Miss

19 Apr 2022

News You Might Have Missed: April 19th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed....

By Jason Najum

Finance

15 Apr 2022

Mydecine Announces Reverse Stock-Split

Mydecine announced an upcoming reverse stock-split....

By Jason Najum

Industry

14 Apr 2022

MindMed to Announce Results for LSD Trial

Today we learned that MindMed collaborators from the University Hospital Basel will present results from their Phase 2 clinical trial of LSD in the treatment of anxiety disorders....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.